Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure

Phase 2 Unknown 80 enrolled National Center for Cardiovascular Research Carlos III Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · collab Hospital Clinic of Barcelona · collab Hospital Universitario 12 de Octubre · collab Puerta de Hierro University Hospital · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of mirabegron (a B3 adrenergic receptor agonist) in patients with pulmonary hypertension secondary to heart failure by conducting a randomized multicenter phase II placebo-controlled clinical trial.

Timeline

Start: 2016-06
Primary completion: 2017-01
Completion: 2019-06

Publications

Garcia-Lunar I, Blanco I, Fernandez-Friera L, Prat-Gonzalez S, Jorda P, Sanchez J, Pereda D, Pujadas S, Rivas M, Sole-Gonzalez E, Vazquez J, Blazquez Z, Garcia-Picart J, Caravaca P, Escalera N, Garcia-Pavia P, Delgado J, Segovia-Cubero J, Fuster V, Roig E, Barbera JA, Ibanez B, Garcia-Alvarez A. Design of the beta3-Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure Trial. JACC Basic Transl Sci. 2020 Mar 11;5(4):317-327. doi: 10.1016/j.jacbts.2020.01.009. eCollection 2020 Apr.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Mirabegron	Other / unclassified	200 mg	Oral

Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure

Summary

Timeline

Publications

Drugs

Indications